Physician profile
Sunil Pathak
NPI 1346692217
$7,437.79
in general payments reported to CMS, 2019-2025
20 companies · $5,469 in 2025
The $5,469 reported for 2025 was more than what 84% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $201 · 2024: $1,768 · 2025: $5,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $1,899 · Travel and Lodging: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $1,898.92 |
| Travel and Lodging | $1,538.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $5,168.58 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Edwards Lifesciences Corporation | $1,215.06 | 2024 | Pascal |
| Inari Medical, INC. | $219.63 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $159.89 | 2024 | Corevalve Evolut R, Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.46 | 2024-2025 | Lifevest |
| Abiomed | $90.03 | 2024 | Impella |
| Pfizer INC. | $70.63 | 2024-2025 | |
| Boston Scientific Corporation | $62.27 | 2023 | |
| Novartis Pharmaceuticals Corporation | $50.51 | 2024-2025 | |
| Abbott Laboratories | $46.42 | 2024 | Cardiomems |
| Amgen INC. | $45.94 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $34.91 | 2025 | |
| Merck Sharp & Dohme LLC | $31.95 | 2023 | Verquvo |
| Stryker Corporation | $27.24 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cordis US Corp. | $26.14 | 2024 | Mynx Control |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.63 | 2025 | Eliquis |
| Atricure, INC. | $18.99 | 2024 | |
| Heartflow, INC. | $18.11 | 2025 | |
| United Therapeutics Corporation | $16.39 | 2025 | Tyvaso |
| Philips North America LLC | $15.01 | 2025 | Azurion 7 M20 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.